{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:09:03Z","timestamp":1791216543776,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,4,12]],"date-time":"2013-04-12T00:00:00Z","timestamp":1365724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1007\/s40291-013-0031-x","type":"journal-article","created":{"date-parts":[[2013,4,11]],"date-time":"2013-04-11T09:23:12Z","timestamp":1365672192000},"page":"233-237","source":"Crossref","is-referenced-by-count":20,"title":["UGT1A1*28 is Associated with Decreased Systemic Exposure of Atorvastatin Lactone"],"prefix":"10.1007","volume":"17","author":[{"given":"Camilla","family":"Stormo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Bogsrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00c5sberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin P.","family":"Piehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjetil","family":"Retterst\u00f8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne K.","family":"Kringen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,12]]},"reference":[{"issue":"9753","key":"31_CR1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"3","key":"31_CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","volume":"33","author":"YS Chatzizisis","year":"2010","unstructured":"Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33(3):171\u201387.","journal-title":"Drug Saf"},{"issue":"8","key":"31_CR3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","volume":"359","author":"E Link","year":"2008","unstructured":"Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy\u2014a genome wide study. N Engl J Med. 2008;359(8):789\u201399.","journal-title":"N Engl J Med"},{"issue":"6","key":"31_CR4","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.clpt.2006.02.014","volume":"79","author":"M Hermann","year":"2006","unstructured":"Hermann M, Bogsrud MP, Molden E, et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther. 2006;79(6):532\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"31_CR5","first-page":"1369","volume":"28","author":"W Jacobsen","year":"2000","unstructured":"Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000;28(11):1369\u201378.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"31_CR6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/dmd.104.002477","volume":"33","author":"C Chen","year":"2005","unstructured":"Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005;33(4):537\u201346.","journal-title":"Drug Metab Dispos"},{"issue":"4\u20135","key":"31_CR7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejps.2007.12.009","volume":"33","author":"IB Skottheim","year":"2008","unstructured":"Skottheim IB, Gedde-Dahl A, Hejazifar S, et al. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci. 2008;33(4\u20135):317\u201325.","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"31_CR8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF03256413","volume":"15","author":"IB Skottheim","year":"2011","unstructured":"Skottheim IB, Bogsrud MP, Hermann M, et al. Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy. Mol Diagn Ther. 2011;15(4):221\u20137.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"31_CR9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2009.181","volume":"87","author":"S Riedmaier","year":"2010","unstructured":"Riedmaier S, Klein K, Hofmann U, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther. 2010;87(1):65\u201373.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"31_CR10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/FPC.0b013e3283544085","volume":"22","author":"SK Cho","year":"2012","unstructured":"Cho SK, Oh ES, Park K, et al. The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. Pharmacogenet Genomics. 2012;22(8):598\u2013605.","journal-title":"Pharmacogenet Genomics"},{"key":"31_CR11","unstructured":"Court MH. Michael H. Court\u2019s (2005\u20132008) online calculator. Tufts University web site. 2 May 22011. http:\/\/www.tufts.edu\/~mcourt01\/Documents\/Court%20lab%20-%20HW%20calculator.xls. . Accessed 26 Mar 2012."},{"key":"31_CR12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2105-7-60","volume":"7","author":"KW Carter","year":"2006","unstructured":"Carter KW, McCaskie PA, Palmer LJ. JLIN: a java based linkage disequilibrium plotter. BMC Bioinforma. 2006;7:60.","journal-title":"BMC Bioinforma"},{"issue":"5","key":"31_CR13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","volume":"30","author":"T Prueksaritanont","year":"2002","unstructured":"Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos. 2002;30(5):505\u201312.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"31_CR14","first-page":"106","volume":"84","author":"A Iolascon","year":"1999","unstructured":"Iolascon A, Faienza MF, Centra M, et al. (TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert\u2019s syndrome. Haematologica. 1999;84(2):106\u20139.","journal-title":"Haematologica"},{"issue":"6","key":"31_CR15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.clpt.2006.02.013","volume":"79","author":"R Laaksonen","year":"2006","unstructured":"Laaksonen R. On the mechanisms of statin-induced myopathy. Clin Pharmacol Ther. 2006;79(6):529\u201331.","journal-title":"Clin Pharmacol Ther"},{"issue":"17","key":"31_CR16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","volume":"54","author":"D Voora","year":"2009","unstructured":"Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609\u201316.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"31_CR17","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","volume":"95","author":"E Beutler","year":"1998","unstructured":"Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A. 1998;95(14):8170\u20134.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-013-0031-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40291-013-0031-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-013-0031-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T22:23:41Z","timestamp":1559514221000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40291-013-0031-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,12]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["31"],"URL":"https:\/\/doi.org\/10.1007\/s40291-013-0031-x","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,12]]}}}